Furthermore, given that the patients with high pre-treatment CD38 levels on MM cells have a better response to Daratumumab monotherapy, high CD38 expression on MM cells seems satisfactory to maximize the clinical efficacy such as the combination treatment of CD16F158V CD38low NK cells and Daratumumab 120. The gene discussed is CD38; the disease is Miyoshi myopathy.